Bakkt, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Bakkt posted Q2 2026 GAAP net income of $80.8M ($1.96 per share), primarily driven by a $98.5M non-cash gain from the fair value increase of 47.5M Transchem warrants allotted in June 2026 (Bakkt paid ~$9.4M initially, with ~$28.2M remaining subscription due). Excluding warrant fair-value gains, Adjusted EBITDA loss was $11.8M. Total Transacting Volume was $168.8M in Q2 and $410M H1 2026; cash position is $50.7M with no long-term debt.
Why this rating
Large non-cash warrant gain ($98.5M) inflates reported earnings but masks $11.8M operating EBITDA loss. Warrant position ($107.9M fair value) now equals 116% of company's $92.8M market cap—material strategic asset. DTR acquisition integration ongoing; Q4 2026 product launches are speculative. Real operating momentum unclear; metric-heavy guidance creates execution risk relative to company size.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.